RCAG
NKTR icon

Rehmann Capital Advisory Group’s Nektar Therapeutics NKTR Stock Holding History

Rehmann Capital Advisory Group’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		$1.13K Buy
+4
New +$1.47K ﹤0.01% 1537
2019
Q2 		– Hold
0
– – – 2033
2019
Q1 		– Hold
0
– – – 2050
2018
Q3 		– Sell
-1
Closed -$879 – 2165
2018
Q2 		$879 Buy
+1
New +$1.15K ﹤0.01% 2000

Other funds holding NKTR

Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Rehmann Capital Advisory Group's NKTR Position: Q3 2019 in Review

Rehmann Capital Advisory Group opened a new position in Nektar Therapeutics (NKTR) in Q3 2019: 4 shares worth $1.13K. The stake represents ﹤0.01% of the portfolio and ranks #1537 among its holdings. This is a return to the name: Rehmann Capital Advisory Group previously reported a position in NKTR as recently as Q2 2018.

Rehmann Capital Advisory Group first reported a position in NKTR in Q2 2018 and has held it in 2 quarters since. 288 funds tracked by Wall St. Rank hold NKTR as of Q3 2019.

  • Rehmann Capital Advisory Group held 4 shares of Nektar Therapeutics worth $1.13K as of Q3 2019.
  • Nektar Therapeutics was a new Rehmann Capital Advisory Group position in Q3 2019.
  • Nektar Therapeutics made up ﹤0.01% of Rehmann Capital Advisory Group's portfolio in Q3 2019, its #1537 holding.
  • Rehmann Capital Advisory Group first reported a position in Nektar Therapeutics in Q2 2018 and has held it in 2 quarters since.
  • 288 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q3 2019.

Based on Rehmann Capital Advisory Group's 13F filing for Q3 2019, filed 2 Jan 2020.